ICER
ICER
  • ICER Analytics™
  • Donate
  • Who We Are
    • History & Impact
    • People
    • Independent Funding
    • Frequently Asked Questions (FAQs)
  • Our Approach
    • Methods & Process
    • Policies
  • Engage with ICER
    • Patients
    • Clinicians
    • Manufacturers
    • Prospective Employees
    • Committees & Boards
  • News & Insights
    • Press Releases
    • Commentaries
    • Journal Articles
    • Weekly View
  • Explore Our Research
    • Assessments
    • Policy Papers
    • ICER Calendar
    • ICER ANALYTICS™

Explore Our Research

Over the past decade, we have developed over 75 reports that describe how Americans can work towards fair access and fair pricing while incentivizing future innovation.

Assessments

Our comparative clinical effectiveness analyses for specific disease areas

Filter All Assessments

Policy Papers

Analyses on current issues and potential solutions in the US healthcare system

Filter All Policy Papers

ICER Calendar

View all key upcoming dates

Learn More

ICER Analytics®

A subscription service that includes streamlined use of our analyses so you can make the best decisions

Visit Our Analytics Site

Featured Reports, News & Insights

woman listening to news at a party

Due to Aducanumab’s New PDUFA Date, ICER Extends Timeline for Alzheimer’s Disease Assessment

ICER extended the timeline for assessing the comparative clinical effectiveness and value of aducanumab (Biogen) for the treatment of Alzheimer’s disease.

02/10/2021

ICER Identifies Most Significant 2019 US Drug-Price Hikes — Even After Rebates — That Were Not Supported by New Clinical Evidence

Out of 10 identified drugs that had substantial 2019 price increases on top of already high current spending, seven were not supported by new clinical evidence; the net price increases on these seven drugs alone cost Americans an additional $1.2 billion in annual drug spend.

01/12/2021

ICER Publishes Evidence Report on Roxadustat for Treating Anemia in Chronic Kidney Disease

Other than a proven ability to reduce the need for IV iron supplements, the evidence is insufficient to determine if roxadustat is safer or more effective than ESAs; possibility exists for greater mortality than ESAs.

01/28/2021
Go to News & Insights
Back to Top
  • Contact
  • Careers
  • Find a Report
  • Donate
  • ICER ANALYTICS™ LOGIN

OUR NEWSLETTER.

A weekly digest of the top news
on ICER and US drug pricing. Sign Up


CONTACT US

Institute for Clinical and Economic Review
Two Liberty Square, Ninth Floor, Boston, MA 02109
Get Directions

+1 (617) 528-4013

Email: info@icer.org

Media Inquiries: mediainquiries@icer.org

ICER
© ICER, 2021
  • Terms and Conditions
  • Privacy Policy
Twitter Linkedin